38
Participants
Start Date
December 31, 2007
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
Recombinant Factor VIII (Kogenate, BAY 14-2222)
Subjects electing to stay on the prophylactic treatment (prospective)
Recombinant Factor VIII (Kogenate, BAY 14-2222)
Subjects electing to switch to on-demand treatment (prospective)
Recombinant Factor VIII (Kogenate, BAY 14-2222)
Subjects remaining on-demand treatment (retrospective)
Peoria
Jefferson City
Fort Worth
Houston
Denver
Las Vegas
Duarte
Many Locations
Many Locations
Many Locations
Lead Sponsor
Bayer
INDUSTRY